Pfizer beats by $0.16, beats on revs; reaffirms FY25 EPS guidance, revs guidance (26.20)
- Reports Q4 (Dec) earnings of $0.63 per share, excluding non-recurring items, $0.16 better than the FactSet Consensus of $0.47; revenues rose 24.7% year/year to $17.76 bln vs the $17.39 bln FactSet Consensus.
- Excluding contributions from Comirnaty and Paxlovid, fourth-quarter 2024 operational revenue growth was driven primarily by:
- Global revenues of $915 million from legacy Seagen compared with $132 million of revenue in fourth-quarter 2023 following the completion of the acquisition in mid-December 2023;
- Vyndaqel family (Vyndaqel, Vyndamax, Vynmac) globally, up 60% operationally, driven largely by strong demand with continuing uptake in patient diagnosis, primarily in the U.S. and international developed markets, as well as increased affordability in the U.S;
- Eliquis globally, up 13% operationally, driven primarily by continued oral anti-coagulant adoption and market share gains in the non-valvular atrial fibrillation indication in the U.S. and certain markets in Europe, partially offset by declines due to loss of patent-based exclusivity and generic competition in certain international markets
- Co reaffirms guidance for FY25, sees EPS of $2.80-$3.00, excluding non-recurring items, vs. $2.91 FactSet Consensus; sees FY25 revs of $61.0-$64.0 bln vs. $63.07 bln FactSet Consensus.